CD80 and cancer: Interestingly, our findings demonstrate that most epithelial cancer cells express PD-L1, whereas hybrid E/M and mesenchymal cancer cells reduce PD-L1 expression and upregulate CD80 and CD155 expression, which are the ligands of CTLA-4 and TIGIT receptors.